Who is sponsoring NCT05715606?

NCT05715606 is sponsored by Anhui Provincial Hospital.

What drugs are being tested in NCT05715606?

Interventions in NCT05715606: Metabolically Armed CD19 CAR-T cells.

What condition does NCT05715606 study?

NCT05715606 studies Diffuse Large B-cell Lymphoma.

Is NCT05715606 still recruiting?

NCT05715606 is currently status unknown. Last updated 5 July 2023.

Last reviewed 2023-07-05 · How we verify

NCT05715606

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Status unknown EARLY_PHASE1 Last updated 5 July 2023

What this trial tests

EARLY_PHASE1 trial testing Metabolically Armed CD19 CAR-T cells in Diffuse Large B-cell Lymphoma in 18 participants. Status unknown.

Timeline

10 February 2023

Primary endpoint
1 February 2025

15 May 2025

Quick facts

Lead sponsor	Anhui Provincial Hospital
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	10 February 2023
Primary completion	1 February 2025
Estimated completion	15 May 2025
Sites	1 location across China

Drugs / interventions tested

Metabolically Armed CD19 CAR-T cells — full drug profile →

Conditions studied

Diffuse Large B-cell Lymphoma — all drugs for Diffuse Large B-cell Lymphoma →

Sponsor

Anhui Provincial Hospital

Who can join

18 and older, any sex, with Diffuse Large B-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting metabolism to improve CAR-T cells therapeutic efficacy.
Liu S, Zhao Y, Gao Y, Li F, et al · · 2024 · cited 8× · PMID 38501360 · DOI 10.1097/cm9.0000000000003046
Targeting cancer-associated glycosylation for adoptive T cell therapy of gastro-intestinal and gynecological cancers
Zingg A, Ritschard R, Thut H, Buchi M, et al · · 2024 · cited 1× · DOI 10.1101/2024.09.12.612750
EHA2024 Hybrid Congress
· 2024

Verify or expand the search:

Other trials of Metabolically Armed CD19 CAR-T cells

Trials testing the same drug.

NCT06711146 — Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SL · EARLY_PHASE1 · recruiting
NCT06716164 — Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research · EARLY_PHASE1 · recruiting
NCT06393335 — Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory C · EARLY_PHASE1 · recruiting
NCT06120166 — Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research · EARLY_PHASE1 · recruiting
NCT05747157 — Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research · EARLY_PHASE1 · unknown

Other recruiting trials for Diffuse Large B-cell Lymphoma

Currently open trials in the same condition.

NCT06977711 — Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large · Phase 1 · recruiting
NCT06846463 — Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ · Phase 2 · recruiting
NCT06870487 — A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers · Phase 1 · active not recruiting
NCT06651853 — Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL · Phase 2 · recruiting
NCT06503263 — Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL · Phase 2 · recruiting

Other Anhui Provincial Hospital trials

Trials by the same sponsor.

NCT07523464 — Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC · Phase 1 · not yet recruiting
NCT07481656 — Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) · Phase 4 · not yet recruiting
NCT07462676 — Simultaneous Vs Staged VPS and CP :A Multi-cnter RCT. · NA · not yet recruiting
NCT07211048 — Anti CD19 Gene Therapy for B-cell Lymphoma · NA · recruiting
NCT07279844 — An Open-label, Observational, Long-term Follow-up Study Evaluating the Safety and Efficacy of RGL-193 Putamen Injection · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05715606 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anhui Provincial Hospital
Last refreshed: 5 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05715606.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing